|
Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes
|
Apr 2016
|
Anemia
|
myelodysplastic syndromes (MDS)
|
|
Spontaneous remision of aplastic anemia occurring during a pregnancy
|
Aug 2012
|
Ann Biol Clin (Paris)
|
aplastic anemia
|
|
Myelodysplastic syndromes: pathophysiology, clinical and biological features
|
Dec 2015
|
Ann Biol Clin (Paris)
|
myelodysplastic syndromes (MDS)
|
|
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
|
Sep 2013
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide
|
May 2014
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol
|
Aug 2016
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Multiparameter FLAER-based flow cytometry for screening of paroxysmal nocturnal hemoglobinuria enhances detection rates in patients with aplastic anemia
|
Dec 2014
|
Ann Hematol
|
aplastic anemia
|
|
Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
|
Oct 2015
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia
|
Aug 2017
|
Ann Hematol
|
aplastic anemia
|
|
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
|
Sep 2016
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
